Espironolactona en la coriorretinopatía central serosa

  1. Pedro Rocha Cabrera
  2. L. M. Cordovés Dorta
  3. Denisse Ángel Pereira
  4. J Rodríguez Martín
  5. C Peña Betancor
  6. Jacob Lorenzo Morales
Journal:
Archivos de la Sociedad Canaria de Oftalmología

ISSN: 0211-2698

Year of publication: 2016

Issue: 27

Pages: 96-100

Type: Article

Export: RIS

Abstract

Case report: 43-year-old male with no relevant medical history, referred for eccrine hydrocystoma surgery in lower eyelid, left eye. A week after, he shows a decreased visual acuity as well as a central serous chorioretinopathy that did not improve spontaneously and persisted over time for eight months until the treatment with spironolactone, 50 mg daily, was prescribed and the retinal disease eventually resolved. Discussion: There is evidence that spironolactone is able to antagonise the aldosterone receptors in the retina. Its efficacy has been proved and can be foreseen as a promising drug in the treatment of this retinal disease.